The adoption of value-based health care concepts among US providers is happening, albeit slowly. In what is an unusual reversal of pioneering health care concepts, the pace is being set elsewhere – in Europe – rather than in the US, even if the direction of travel has been firmly established. Boston Consulting Group experts give In Vivo an interim update on the progress and outlook for VBHC.
In matters of the delivery of value-based health care (VBHC), it helps to lay out a few basic tenets. One key fact to consider is that not every medical technology solution or technology provider fits into the value discussion that is currently preoccupying providers, manufacturers of medtech innovations and payers.
Jens Deerberg-Wittram, MD, a director at Boston Consulting Group based in Munich, Germany, tells In Vivo that there are certain...
Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
The whirlwind back-and-forth on US tariffs and Robert F. Kennedy jr.’s plans to deregulate health care have become all-preoccupying, but the National Academy of Medicine was first to set out President Trump’s health administration priorities.
Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”
While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
